Intron A Hepatitis C

Description

Intron A (interferon alfa-2b)

Background
Hepatitis C is a viral disease caused by the hepatitis C virus (HCV) that leads to inflammation of the liver. Most people who were recently infected with hepatitis C do not have symptoms, but most people infected with hepatitis C develop a chronic infection. Untreated, chronic infection can lead to liver cirrhosis and/or liver cancer. Six genotypes of the hepatitis C virus exist and genotyping is essential to effective treatment. Hepatitis C infection may be detected in the blood by the HCV RNA assay. Disease status may be monitored by assays of biochemical liver tests or liver biopsy (1).

The goals of HCV treatment are to remove the virus from the blood and reduce the risk of cirrhosis and liver cancer that can result from long-term HCV infection. The most common treatment regimens are based on combinations of pegylated interferon alfa, ribavirin, and a protease inhibitor. In some cases, treatment with a single agent or two agents is most appropriate (1).

Regulatory Status (limited to hepatitis C)
FDA-approved indication: Intron A is an alpha interferon indicated for the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive. Studies in these patients demonstrated that Intron A therapy can produce clinically meaningful effects on this
disease, manifested by normalization of serum alanine aminotransferase (ALT) and reduction in liver necrosis and degeneration (2).

All alpha interferons, including Intron A, carry a boxed warning that they can cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping Intron A therapy (2).

A liver biopsy should be performed to establish the diagnosis of chronic hepatitis. Patients should be tested for the presence of antibody to HCV. Patients with other causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior to initiation of Intron A therapy, the physician should establish that the patient has compensated liver disease. The following patient entrance criteria for compensated liver disease were used in the clinical studies and should be considered before Intron A treatment of patients with chronic hepatitis C (2):

- No history of hepatic encephalopathy, variceal bleeding, ascites, or other clinical signs of decompensation
- Bilirubin Less than or equal to 2 mg/dL
- Albumin Stable and within normal limits
- Prothrombin Time Less than 3 seconds prolonged
- WBC Greater than or equal to 3000/mm³
- Platelets Greater than or equal to 70,000/mm³
- Serum creatinine should be normal or near normal (2).

Prior to initiation of Intron A therapy, CBC and platelet counts should be evaluated in order to establish baselines for monitoring potential toxicity. These tests should be repeated at Weeks 1 and 2 following initiation of Intron A therapy, and monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals to assess response to treatment (2).

Patients with preexisting thyroid abnormalities may be treated if thyroid stimulating hormone (TSH) levels can be maintained in the normal range by medication. TSH levels must be within normal limits upon initiation of Intron A treatment and TSH testing should be repeated at 3 and 6 months (2).
Non-pegylated interferons, such as Intron A are generally considered inferior to pegylated interferons, such as Pegasys and Pegintron (2).

**Related policies**
Actimmune, Alferon N, Pegasys, Pegintron

**Policy**
This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Intron A may be considered **medically necessary** for the treatment of hepatitis C in patients 18 years of age or older who have chronic hepatitis C and if the conditions indicated below are met.

Intron A may be considered **investigational** in patients less than 18 years of age and for all other indications.

**Prior-Approval Requirements**

**Age**
18 years of age or older

**Diagnosis**
Patient must have the following:
1. Chronic hepatitis C confirmed by liver biopsy, a history of blood or blood product exposure, or positive antibodies to hepatitis C

AND ALL of the following:
1. Compensated liver disease
2. NOT an immunosuppressed transplant recipient
3. Must NOT be an appropriate candidate for treatment with a pegylated interferon in combination with ribavirin and a protease inhibitor
4. Significant intolerance or contraindication to ribavirin (examples include hemoglobin level below 8.5 g/dL, a hemoglobinopathy such as thalassemia major or sickle-cell anemia)
5. NOT pregnant
6. NO history of unstable heart disease

**Prior – Approval Renewal Requirements**
None
**Policy Guidelines**

**Pre - PA Allowance**
None

**Prior - Approval Limits**

**Duration** 12 months

**Rationale**

**Summary**
Hepatitis C is a viral disease caused by the hepatitis C virus (HCV) that leads to inflammation of the liver. Untreated, chronic infection can lead to liver cirrhosis and/or liver cancer. The most common treatment regimens are based on combinations of pegylated interferon alfa, ribavirin, and a protease inhibitor. In some cases, treatment with a single agent or two agents is most appropriate (1-2).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Intron A while maintaining optimal therapeutic outcomes.

**References**

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2004</td>
<td>Criteria updated to reflect current guidelines:</td>
</tr>
<tr>
<td></td>
<td>NIH Consensus Statement on Management of Hepatitis C: 2002</td>
</tr>
<tr>
<td></td>
<td>NIH Consensus Statements and State-of-the-Science Statements</td>
</tr>
<tr>
<td></td>
<td>Volume 19, Number 3, June 10-12, 2002</td>
</tr>
<tr>
<td></td>
<td>National Institutes of Health, Office of the Director</td>
</tr>
<tr>
<td></td>
<td>Diagnosis, Management, and Treatment of Hepatitis C</td>
</tr>
<tr>
<td></td>
<td>American Association for the Study of Liver Diseases</td>
</tr>
<tr>
<td></td>
<td>Hepatology, April 2004</td>
</tr>
<tr>
<td>Section:</td>
<td>Prescription Drugs</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Subsection:</td>
<td>Anti-Infective Agents</td>
</tr>
<tr>
<td>Subject:</td>
<td>Intron A Hepatitis C</td>
</tr>
</tbody>
</table>

September 2011  Section 2 (Hepatitis C Monotherapy) reviewed and revised to follow the current Intron A package insert, as follows: Intron A is indicated for the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are hepatitis C viral antibody positive. A liver biopsy should be performed to establish the diagnosis of chronic hepatitis (2). Criteria will not be renewable after 6 months of therapy (2). Liver transplant removed from criteria and renewal will not be allowed (2).

September 2012  Annual editorial review and reference update
March 2014      Annual editorial review and reference update
March 2015      Annual editorial review and reference update
March 2016      Annual editorial review and reference update
 Policy number changed from 5.03.05 to 5.01.05

December 2017   Annual review and reference update
November 2018   Annual editorial review and reference update. Removal of examples of protease inhibitors
December 2019   Annual review and reference update

**Keywords**

This policy was approved by the FEP Pharmacy and Medical Policy Committee on December 6, 2019 and is effective January 1, 2020.